Resultados de la búsqueda 21-30 of 1393 for ���������������������������op������r���:za33���

  1. Mayo Clinic Physician Update - July 2024

    Page 1.

  2. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  7. Cirugía - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate long-term symptom resolution and quality of life improvements after operative management of popliyteal artery ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...